drugset / Trial / NCT00752973

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

NCT00752973

Phase 2/3 Completed 12 enrolled Sun Pharmaceutical Industries, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.

Timeline

Start
2008-09
Primary completion
2011-12
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Malathion Small molecule 0.5 % Topical